Cargando…

Treatment Limitation Decisions in Critically Ill Patients With a Malignancy on the Intensive Care Unit

BACKGROUND: Treatment limitation decisions (TLDs) on the ICU can be challenging, especially in patients with a malignancy. Up-to-date literature regarding TLDs in critically ill patients with a malignancy admitted to the ICU is scarce. The aim was to compare the incidence of written TLDs between pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Zee, Esther N., Epker, Jelle L., Bakker, Jan, Benoit, Dominique D., Kompanje, Erwin J. O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review of a Large Clinical Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705645/ https://www.ncbi.nlm.nih.gov/pubmed/32787659 http://dx.doi.org/10.1177/0885066620948453

Ejemplares similares

Outcome of cancer patients considered for intensive care unit admission in two university hospitals in the Netherlands: the danger of delayed ICU admissions and off-hour triage decisions
por: van der Zee, Esther N., et al.
Publicado: (2021)

Assessment of mortality and performance status in critically ill cancer patients: A retrospective cohort study
por: van der Zee, Esther N., et al.
Publicado: (2021)

Respiratory support withdrawal in intensive care units: international differences stressed and straightened!
por: Epker, Jelle L, et al.
Publicado: (2011)

Extended Reality Use in Paediatric Intensive Care: A Scoping Review
por: Goldsworthy, Adrian, et al.
Publicado: (2023)

Making a dead woman pregnant? A critique of the thought experiment of Anna Smajdor
por: Kompanje, Erwin J.O., et al.
Publicado: (2023)

One-year Mortality of Cancer Patients with an Unplanned ICU Admission: A Cohort Analysis Between 2008 and 2017 in the Netherlands
por: van der Zee, Esther N., et al.
Publicado: (2021)

Engaging People in Making History: Impact, Public Engagement and the World Beyond the Campus
por: King, Laura, et al.
Publicado: (2015)

Risk factors for shedding of Salmonella enterica among hospitalized large animals over a 10‐year period in a veterinary teaching hospital
por: Burgess, Brandy A., et al.
Publicado: (2019)

The Prevalence of Compassion Fatigue and Burnout among Healthcare Professionals in Intensive Care Units: A Systematic Review
por: van Mol, Margo M. C., et al.
Publicado: (2015)

Continuous Renal Replacement Therapy (CRRT) for Nonrenal Indications among Critically Ill Children with Malignancy
por: Hui, Wun Fung, et al.
Publicado: (2021)

The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy
por: Puttemans, Janik, et al.
Publicado: (2022)

Accidental methanol ingestion: Case report
por: Epker, Jelle L, et al.
Publicado: (2010)

SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
por: Lyon, Robert P., et al.
Publicado: (2023)

Interleukin-6: obstacles to targeting a complex cytokine in critical illness
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Comment on “Attitudes of European physicians, nurses, patients, and families regarding end-of-life decisions: the ETHICATT study” by Sprung et al.
por: Vrakking, Astrid M., et al.
Publicado: (2007)

Incorporating fine‐scale environmental heterogeneity into broad‐extent models
por: Graham, Laura J., et al.
Publicado: (2019)

Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
por: Grinkevitch, Vera, et al.
Publicado: (2022)

Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization
por: Buongervino, Samantha, et al.
Publicado: (2021)

Spatial transcriptional signatures define margin morphogenesis along the proximal–distal and medio-lateral axes in tomato (Solanum lycopersicum) leaves
por: Martinez, Ciera C, et al.
Publicado: (2020)

A FZD7-specific Antibody–Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models
por: Do, Myan, et al.
Publicado: (2022)

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
por: Pegram, Mark D., et al.
Publicado: (2021)

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo
por: Montes de Oca, Rocio, et al.
Publicado: (2021)

Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers
por: Klempner, Samuel J., et al.
Publicado: (2021)

A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway
por: Wurm, Melanie, et al.
Publicado: (2021)

A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
por: DaSilva, John O., et al.
Publicado: (2021)

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
por: Harper, James, et al.
Publicado: (2021)

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
por: Gordon, Michael S., et al.
Publicado: (2021)

Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
por: Wang, Beatrice T., et al.
Publicado: (2021)

Identification and functional annotation of long intergenic non-coding RNAs in Brassicaceae
por: Palos, Kyle, et al.
Publicado: (2022)

Leaf cell-specific and single-cell transcriptional profiling reveals a role for the palisade layer in UV light protection
por: Procko, Carl, et al.
Publicado: (2022)

Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
por: Hooper, Andrea T., et al.
Publicado: (2022)

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
por: Tomar, Sakshi, et al.
Publicado: (2022)

Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers
por: Zammarchi, Francesca, et al.
Publicado: (2022)

Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers
por: Hollmén, Maija, et al.
Publicado: (2022)

DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models
por: Yamato, Michiko, et al.
Publicado: (2022)

Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
por: Buonato, Janine M., et al.
Publicado: (2022)

Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer
por: Wang, Peiyin, et al.
Publicado: (2022)

ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors
por: Wiedemeyer, Wolf R., et al.
Publicado: (2022)

Rapid growth of Moso bamboo (Phyllostachys edulis): Cellular roadmaps, transcriptome dynamics, and environmental factors
por: Chen, Ming, et al.
Publicado: (2022)

Diversification of heat shock transcription factors expanded thermal stress responses during early plant evolution
por: Wu, Ting-Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_plvrtbufrrc4lvadses5bbdlf7